Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.
Neuroscience
Posted inNeuroscience, New Drugs, Regulatory
Lybalvi: New Drug for Schizophrenia and Bipolar I Disorder
Combination of olanzapine and samidorphan will prevent unwanted weight gain in patients.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Posted inNeuroscience, New Drugs, Regulatory
Zynrelef: New Drug for Postoperative Pain Relief
A proprietary formulation of bupivacaine with meloxicam, developed by Heron Therapeutics, relieves acute pain for 72 hours after surgery.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Posted inNeuroscience, New Drugs, Regulatory
Reyvow: Completely New Drug for Acute Treatment of Migraine
In the task of getting rid of headaches lasmiditan by Eli Lilly is as effective as the popular triptans, but safer.
Posted inClinical Trials, Neuroscience
Masitinib for Alzheimer’s Disease: It Did Work!
Masitinib by AB Science has curbed cognitive deterioration in Alzheimer-type dementia. And that’s a new hope.